SCHEMBL974110

SCHEMBL974110

COc1ccccc1-c1ccccc1C(=O)NO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.53
CDK4 P11802 1/20 0.50
CCND1 P24385 1/20 0.50
STAT3 P40763 1/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
KCNK3 O14649 1/20 0.47
KCNK9 Q9NPC2 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MPO P05164 1/20 0.47
GAA P10253 1/20 0.47
HIF1A Q16665 1/20 0.47
TSHR P16473 2/20 0.47
HTT P42858 2/20 0.47
KMT2A Q03164 2/20 0.47
TP53 P04637 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HDAC1 Q13547 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12922051 0.87 CTSD (0.47) CTSDSTAT3NPC1RAB9AKCNK3
SCHEMBL978349 0.87 NPC1 (0.49) CTSDSTAT3NPC1RAB9ASMN1; SMN2
SCHEMBL6671288 0.85 CTSD (0.70) CTSDSTAT3NPC1RAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL31097029 0.84 CTSD (0.68) CTSDSTAT3NPC1RAB9ASMN1; SMN2
SCHEMBL3026631 0.83 GAA (0.64) SMN1; SMN2KDM4EMPOGAAHIF1A
SCHEMBL7174241 0.82 SLC6A3 (0.60) CTSDSMN1; SMN2KDM4EGAATSHR
SCHEMBL30285248 0.82 SLC6A3 (0.60) CTSDSMN1; SMN2KDM4EGAATSHR
SCHEMBL19283347 0.81 CTSD (0.51) CTSDCDK4CCND1STAT3NPC1
SCHEMBL536179 0.80 HTT (0.62) KDM4ETSHRHTTKMT2AALDH1A1
SCHEMBL1957953 0.80 SMN1; SMN2 (0.56) CTSDSTAT3NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673911-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2014-03-18 US disclosed
US-8673911-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2014-03-18 US disclosed
US-8673911-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2014-03-18 US disclosed
US-20140045850-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2014-02-13 US disclosed
US-20140045850-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2014-02-13 US disclosed
US-20140045850-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2014-02-13 US disclosed
US-20110021771-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2011-01-27 US disclosed
US-20110021771-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2011-01-27 US disclosed
EP-2217588-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-08-18 EP disclosed
WO-2009055917-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-05-07 WO disclosed
WO-2009055917-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021771-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC3 CTSD 634/4885CDK4 1597/4885CCND1 1416/4885
US-20140045850-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC3 CTSD 634/4885CDK4 1597/4885CCND1 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.